

I DT03 Rec'd PCT/PTO 26 NOV 2004 PCT

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

|  |  |                        |                  |
|--|--|------------------------|------------------|
|  |  | Application Number     | 10/512,001       |
|  |  | Filing Date            | October 18, 2004 |
|  |  | First Named Inventor   | Alcide Barberis  |
|  |  | Art Unit               | Not Yet Assigned |
|  |  | Examiner Name          | Not Yet Assigned |
| Total Number of Pages in This Submission |  | Attorney Docket Number | 27656/40537      |

### ENCLOSURES (Check all that apply)

|   |   |   |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form                             | <input type="checkbox"/> Drawing(s)   | <input type="checkbox"/> After Allowance Communication to TC                            |
| <input type="checkbox"/> Fee Attached                                     | <input type="checkbox"/> Licensing-related Papers                                       | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences     |
| <input type="checkbox"/> Amendment/Reply                                  | <input type="checkbox"/> Petition   | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final                                      | <input type="checkbox"/> Petition to Convert to a Provisional Application               | <input type="checkbox"/> Proprietary Information  |
| <input type="checkbox"/> Affidavits/declaration(s)                        | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input type="checkbox"/> Status Letter  |
| <input type="checkbox"/> Extension of Time Request                        | <input type="checkbox"/> Terminal Disclaimer  | <input type="checkbox"/> Other Enclosure(s) (please identify below):                    |
| <input type="checkbox"/> Express Abandonment Request                      | <input type="checkbox"/> Request for Refund   |   |
| <input checked="" type="checkbox"/> Information Disclosure Statement      | <input type="checkbox"/> CD, Number of CD(s) _____                                      |   |
| <input type="checkbox"/> Certified Copy of Priority Document(s)           | <input type="checkbox"/> Landscape Table on CD  |   |
| <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application   |   |   |
| <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 |   |   |
| Remarks   |   |   |


### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

|              |                                |          |        |
|--------------|--------------------------------|----------|--------|
| Firm Name    | MARSHALL, GERSTEIN & BORUN LLP |          |        |
| Signature    |                                |          |        |
| Printed name | Jeffrey S. Sharp               |          |        |
| Date         | November 23, 2004              | Reg. No. | 31,879 |

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 23, 2004

Signature: (Jeffrey S. Sharp)



PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/512,001

Attorney Docket No.: 27656/40537

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on November 23, 2004  
Date

Signature

Jeffrey S. Sharp

Typed or printed name of person signing Certificate

31,879  
Registration Number, if applicable

(312) 474-9578  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (11 References)

O I P E J C R S  
NOV 26 2004  
PATENT & TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage for First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 23, 2004 Signature:

J S Sharp

Docket No.: 27656/40537  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

**Alcide BARBERIS et al.**

Application No.: 10/512,001

Filed: October 18, 2004

Art Unit: Not Yet Assigned

For: **METHOD FOR THE  
IDENTIFICATION OF MODULATORS  
OF A SECRETASE ACTIVITY**

Examiner: Not Yet Assigned

### INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A copy of each reference on the PTO/SB/08 is attached.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 27656/40537. A duplicate copy of this paper is enclosed.

Respectfully submitted,


MARSHALL, GERSTEIN & BORUN LLP  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606  
312-474-6300

By:

  
\_\_\_\_\_  
Jeffrey S. Sharp  
Registration No. 31,879  
Attorney for Applicants

November 23, 2004

789417



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**Complete if Known****INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

|       |   |    |   |                        |                  |
|-------|---|----|---|------------------------|------------------|
|       |   |    |   | Application Number     | 10/512,001       |
|       |   |    |   | Filing Date            | October 18, 2004 |
|       |   |    |   | First Named Inventor   | Alcide Barberis  |
|       |   |    |   | Art Unit               | Not Yet Assigned |
|       |   |    |   | Examiner Name          | Not Yet Assigned |
| Sheet | 1 | of | 1 | Attorney Docket Number | 27656/40537      |

**U.S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|---|
|                    |                       | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
| A                  | US-2002025508         | 02-28-2002                               | Klaus Fuchs et al.             |  |   |
| B                  | US-6,333,167          | 12-25-2001                               | David J. Shuey et al.          |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
|                    |                       | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) |                                |  |   |                |
| C                  | DE 199 20 514 A       |   | 11-16-2000                     | Boehringer Ingelheim Pharma                        |   |                |
| D                  | WO 98 13488 A         |   | 04-02-1998                     | Schering AG et al.                                 |   |                |
| E                  | WO 00 34511 A         |   | 06-15-2000                     | Aventis Pharma GmbH                                |   |                |
| F                  | WO 01 62897 A         |   | 08-30-2001                     | Lutgarde Sermeels et al.                           |   |                |
| G                  | WO 01 75088 A         |   | 10-11-2001                     | Esbatech AG et al.                                 |   |                |
| H                  | WO 02 06306 A         |   | 01-24-2002                     | Mark E. Gurney et al.                              |   |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup>  | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------|--|---|----------------|
| I                  | Dixon, E.P. et al., "An Inverse Mamalian Two-Hybrid System For Beta Secretase And Other Proteases," Analytical Biochemistry, Academic Press, San Diego, CA, Vol. 249, No. 2, 1997, Pages 239-241.  |   |                |
| J                  | Feehan, C. et al., "Shedding Of The Lymphocyte L-Selectin Adhesion Molecule Is Inhibited By A Hydroxamic Acid-Based Protease Inhibitor Identification With An L-Selectin-Alkaline Phosphatase Reporter," Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, Vol. 271, No. 12, Pages 7019-7024. |   |                |
| K                  | Karlstrom, Helena et al., "A Sensitive And Quantitative Assay For Measuring Cleavage Of Presenilin Substrates," Journal of Biological Chemistry, Vol. 277, No. 9, Pages 6763-6766.   |   |                |
| L                  | International Search Report corresponding to International Patent Application Serial No. PCT/IB02/01342 dated February 27, 2003, 4 Pages.  |   |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|